Skip to main navigation
Skip to main content
Skip to Footer
Google Tag Manager
US
Novartis site directory
Our Products
US Products By Brand
Patient Assistance
Product Portfolio
Our Process
Therapeutic Areas
Product Related Issues
About Us
Novartis US at a Glance
Who We Are
Diversity & Inclusion
Our Leadership
Research
Contact Us
Corporate Responsibility
Novartis in Society US Reports
External Funding
Corporate Citizenship
Business Conduct
Corporate Integrity Agreement
Payments to HCPs & HCOs
Post-Marketing Commitments
Enhanced Verification Request
News
News Archive
Statements
Stories
US Media Contacts
Novartis US COVID-19 Initiatives
Careers
Careers Search
Working at Novartis
Employee Benefits
Awards & Recognition
NIBR Careers Frequently Asked Questions
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Stories
Filter By
2020
September
Media Release
/
Sep 16, 2020
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
Read More
Media Release
/
Sep 11, 2020
Novartis presents data at ACTRIMS-ECTRIMS on the effects of treatment with Mayzent® (siponimod) studied on disability progression and cognitive processing speed in patients with progressing relapsing multiple sclerosis
Read More
Media Release
/
Sep 11, 2020
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
Read More
August
Media Release
/
Aug 30, 2020
Novartis PARALLAX data provides further evidence of the potential benefit of Entresto® in patients with HFpEF
Read More
Media Release
/
Aug 30, 2020
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Read More
Media Release
/
Aug 27, 2020
Novartis launches PsO in the Know podcast series hosted by music icon Cyndi Lauper
Read More
Media Release
/
Aug 20, 2020
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Read More
Media Release
/
Aug 13, 2020
Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications
Read More
Media Release
/
Aug 05, 2020
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Read More
June
Media Release
/
Jun 24, 2020
Novartis announces FDA filing acceptance of Entresto® (sacubitril/valsartan) for patients with heart failure with preserved ejection fraction (HFpEF)
Read More
Search Results Navigation
First page
« first
Previous page
‹ previous
…
Page
3
of 5
Page
4
of 5
Current page
5
of 5
Page
6
of 5
Page
7
of 5
…
Next page
next ›
Last page
last »
Share
Email
Jump to Comments
Print
Save
Related Links
Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative
Careers in Digital
You are here
Home
›
News
